AAIC 2025 Abstract·23 DecPhase 1b/2a, 6‐month, randomized, double‐blind, placebo‐controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau‐targeted therapeutic in patients with corticobasal syndromeInterventionsPaper